Polarityte (COOL) Upgraded at BidaskClub
BidaskClub upgraded shares of Polarityte (NASDAQ:COOL) from a hold rating to a buy rating in a report released on Saturday.
A number of other brokerages have also weighed in on COOL. ValuEngine lowered shares of Polarityte from a buy rating to a hold rating in a research note on Saturday, July 14th. Cantor Fitzgerald decreased their target price on shares of Polarityte from $70.00 to $65.00 and set a buy rating for the company in a research note on Tuesday, June 12th. Finally, Zacks Investment Research lowered shares of Polarityte from a hold rating to a sell rating in a research note on Tuesday, August 14th.
COOL stock opened at $25.56 on Friday. Polarityte has a 12-month low of $15.21 and a 12-month high of $41.22.
In related news, Director Peter A. Cohen bought 6,000 shares of the firm’s stock in a transaction on Wednesday, July 25th. The stock was acquired at an average cost of $23.20 per share, for a total transaction of $139,200.00. Following the purchase, the director now owns 45,000 shares in the company, valued at $1,044,000. The acquisition was disclosed in a filing with the SEC, which is available through this link. 59.91% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Advisors LLC purchased a new stake in Polarityte during the 2nd quarter valued at $100,000. Bank of Montreal Can purchased a new stake in Polarityte during the 2nd quarter valued at $119,000. Capital Management Associates NY purchased a new stake in Polarityte during the 2nd quarter valued at $200,000. Suntrust Banks Inc. purchased a new stake in Polarityte during the 1st quarter valued at $181,000. Finally, Point72 Asset Management L.P. purchased a new stake in Polarityte during the 2nd quarter valued at $256,000. Institutional investors and hedge funds own 12.58% of the company’s stock.
PolarityTE, Inc operates as commercial-stage biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences.
Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.